27 июн. 2020 г. · This document summarizes the results of a post-hoc analysis of the TWILIGHT trial to evaluate the safety and efficacy of ticagrelor ...

15 окт. 2020 г. · The TWILIGHT trial compared ticagrelor monotherapy to ticagrelor plus aspirin in patients at high risk of bleeding and ischemic events after ...

The TWILIGHT Trial. Sponsoring organization: Icahn School of Medicine at Mount Sinai, NY Funded by AstraZeneca. Coordinated by Icahn School of Medicine at ...

26 сент. 2019 г. · TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy vs. Ticagrelor-Plus-Aspirin Beginning at 3 Months in High-Risk Patients Undergoing PCI.

PowerPoint Presentation. PowerPoint ... We thank all country leaders, investigators, coordinators and study participants who made TWILIGHT possible!

15 февр. 2022 г. · The TWILIGHT trial showed that short-duration DAPT (3 months) followed by ticagrelor monotherapy for 12 months results in less bleeding compared with longer- ...

In particular, the TWILIGHT study showed that monotherapy with the potent P2Y12-receptor inhibitor ticagrelor after 3 months of DAPT was associated with a lower ...

Our trial was designed to examine the effect of withdrawing treatment with aspirin while continuing treatment with ticagrelor alone after 3 months of dual ...

15 мая 2020 г. · A randomized double-blind trial, tested this approach by dropping aspirin at 3 months and continuing with ticagrelor monotherapy for an additional 12 months.

TWILIGHT: Study outcomes. Mehran R et al. N Engl J Med 2019. 7.1%. 4.0%. 3.9%. 3.9%. Death, Nonfatal MI, or Nonfatal Stroke. BARC Type 2, 3, or 5 Bleeding. Page ...